Clinical Trials
13 trialsNCT06915766 2026-05-08
Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis
Cogent Biosciences, Inc.
Available
NCT03601442 2026-04-23
Managed Access Programs for CTL019, Tisagenlecleucel
Novartis
Available
NCT05776134 2026-04-08
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel
Gilead Sciences
Available
NCT07215832 2026-03-02
KEAP
Karyopharm Therapeutics Inc
Available
NCT06799221 2026-02-27
Expanded Access Program for OOS Obe-cel
Autolus Limited
Available
NCT03123029 2026-01-30
Expanded Access to Venetoclax
AbbVie
Available
NCT05619367 2025-12-23
A Compassionate Use (CU) Program of Odronextamab
Regeneron Pharmaceuticals
Available
NCT04400591 2025-12-11
Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol
Juno Therapeutics, a Subsidiary of Celgene
Available
NCT05776160 2025-12-01
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel
Gilead Sciences
Available
NCT01881334 2025-11-20
Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants
Duke University
Available
NCT05974410 2025-10-02
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
AVM Biotechnology Inc
Available
NCT04809233 2025-06-04
Expanded Access to Tipifarnib
Kura Oncology, Inc.
Available
NCT05738538 2025-06-04
Expanded Access to Ziftomenib
Kura Oncology, Inc.
Available